Nothing Special   »   [go: up one dir, main page]

HRP20241082T1 - Konjugati protutijelo-lijek humaniziranog anti-prostata specifičnog membranskog antigena (psma) - Google Patents

Konjugati protutijelo-lijek humaniziranog anti-prostata specifičnog membranskog antigena (psma) Download PDF

Info

Publication number
HRP20241082T1
HRP20241082T1 HRP20241082TT HRP20241082T HRP20241082T1 HR P20241082 T1 HRP20241082 T1 HR P20241082T1 HR P20241082T T HRP20241082T T HR P20241082TT HR P20241082 T HRP20241082 T HR P20241082T HR P20241082 T1 HRP20241082 T1 HR P20241082T1
Authority
HR
Croatia
Prior art keywords
psma
agent
antibody
expressing
additional therapeutic
Prior art date
Application number
HRP20241082TT
Other languages
English (en)
Inventor
Shivarupam BHOWMIK
Jianing Wang
Jinming Xia
William Brady
Feng Tian
Original Assignee
Ambrx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrx, Inc. filed Critical Ambrx, Inc.
Publication of HRP20241082T1 publication Critical patent/HRP20241082T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (9)

1. Konjugat protutijelo-lijek koji sadrži protutijelo anti-prostata specifičnog membranskog antigena (anti-PSMA protutijelo) konjugirano na poveznik lijeka, naznačen time, da se konjugiranje događa preko para-acetil fenilalanina ugrađenog u slijed teškog lanca, pri čemu anti-PSMA protutijelo sadrži slijed teškog lanca SEQ ID NO: 8 i slijed lakog lanca SEQ ID NO: 9, gdje se ugrađuje para-acetil fenilalanin na poziciju A114 teškog lanca u skladu sa shemom Kabat numeriranja, i pri čemu poveznik za lijek je monometil auristatin F koji se ne može rascijepiti i koji ima sljedeću strukturu: [image]
2. Farmaceutski pripravak, naznačen time, da sadrži konjugat protutijelo-lijek prema patentnom zahtjevu 1, i najmanje jedan/jedno farmaceutski prihvatljiv/o adjuvant, vezivno sredstvo, pufer, nosač, razrjeđivač ili pomoćno sredstvo.
3. Farmaceutski pripravak prema patentnom zahtjevu 2, naznačen time, da nadalje sadrži kemoterapeutsko sredstvo, hormonalno sredstvo, antitumorsko sredstvo, imunostimulirajuće sredstvo, imunomodulator, kortikosteroid ili njihovu kombinaciju.
4. Konjugat protutijelo-lijek prema patentnom zahtjevu 1, ili farmaceutski pripravak prema patentnom zahtjevu 2, naznačen time, da je za uporabu u postupku za smanjivanje ili sprečavanje rasta tumora ili progresije raka koji eksprimira PSMA ili stanice raka koja eksprimira PSMA, pri čemu spomenuti postupak obuhvaća stavljanje u doticaj raka koji eksprimira PSMA ili stanicu raka koja eksprimira PSMA s učinkovitom količinom konjugata protutijelo-lijek ili farmaceutskog pripravka.
5. Farmaceutski pripravak prema patentnom zahtjevu 3, naznačen time, da je za uporabu u postupku za smanjivanje ili sprečavanje rasta tumora ili progresije raka koji eksprimira PSMA ili stanice raka koja eksprimira PSMA, pri čemu spomenuti postupak obuhvaća stavljanje u doticaj raka koji eksprimira PSMA ili stanicu raka koja eksprimira PSMA s učinkovitom količinom farmaceutskog pripravka.
6. Konjugat protutijelo-lijek prema patentnom zahtjevu 1, ili farmaceutski pripravak prema patentnom zahtjevu 2, i dodatno terapijsko sredstvo, naznačen/o time, da je za uporabu u postupku za smanjivanje ili sprečavanje rasta tumora ili progresije raka koji eksprimira PSMA ili stanice raka koja eksprimira PSMA, pri čemu spomenuti postupak obuhvaća stavljanje u doticaj raka koji eksprimira PSMA ili stanicu raka koja eksprimira PSMA s učinkovitom količinom konjugata protutijelo-lijek ili farmaceutskog pripravka, i nadalje obuhvaća stavljanje u doticaj raka koji eksprimira PSMA ili stanicu raka koja eksprimira PSMA s učinkovitom količinom dodatnog terapijskog sredstva, gdje dodatno terapijsko sredstvo je kemoterapeutsko sredstvo, hormonalno sredstvo, antitumorsko sredstvo, imunostimulirajuće sredstvo, imunomodulator, kortikosteroid ili njihova kombinacija.
7. Konjugat protutijelo-lijek prema patentnom zahtjevu 1, ili farmaceutski pripravak prema patentnom zahtjevu 2, naznačen time, da je za uporabu s dodatnim terapijskim sredstvom u postupku za smanjivanje ili sprečavanje rasta tumora ili progresije raka koji eksprimira PSMA ili stanice raka koja eksprimira PSMA, pri čemu spomenuti postupak obuhvaća stavljanje u doticaj raka koji eksprimira PSMA ili stanicu raka koja eksprimira PSMA s učinkovitom količinom konjugata protutijelo-lijek ili farmaceutskog pripravka, i nadalje obuhvaća stavljanje u doticaj raka koji eksprimira PSMA ili stanicu raka koja eksprimira PSMA s učinkovitom količinom dodatnog terapijskog sredstva, gdje dodatno terapijsko sredstvo je kemoterapeutsko sredstvo, hormonalno sredstvo, antitumorsko sredstvo, imunostimulirajuće sredstvo, imunomodulator, kortikosteroid ili njihova kombinacija.
8. Dodatno terapijsko sredstvo, naznačeno time, da je za uporabu s konjugatom protutijelo-lijek prema patentnom zahtjevu 1, ili farmaceutskim pripravkom prema patentnom zahtjevu 2, u postupku za smanjivanje ili sprečavanje rasta tumora ili progresije raka koji eksprimira PSMA ili stanice raka koja eksprimira PSMA, pri čemu spomenuti postupak obuhvaća stavljanje u doticaj raka koji eksprimira PSMA ili stanicu raka koja eksprimira PSMA s učinkovitom količinom dodatnog terapijskog sredstva, i nadalje obuhvaća stavljanje u doticaj raka koji eksprimira PSMA ili stanicu raka koja eksprimira PSMA s učinkovitom količinom konjugata protutijelo-lijek prema patentnom zahtjevu 1, ili farmaceutskog pripravka prema patentnom zahtjevu 2, gdje dodatno terapijsko sredstvo je kemoterapeutsko sredstvo, hormonalno sredstvo, antitumorsko sredstvo, imunostimulirajuće sredstvo, imunomodulator, kortikosteroid ili njihova kombinacija.
9. Farmaceutski pripravak; konjugat protutijelo-lijek ili farmaceutski pripravak i dodatno terapijsko sredstvo; konjugat protutijelo-lijek ili farmaceutski pripravak; ili dodatno terapijsko sredstvo; naznačeni time, da su za uporabu u skladu s bilo kojim od patentnih zahtjeva 5-8, gdje dodatno terapijsko sredstvo je hormonalno sredstvo, te time, da hormonalno sredstvo je enzalutamid.
HRP20241082TT 2018-03-29 2019-03-29 Konjugati protutijelo-lijek humaniziranog anti-prostata specifičnog membranskog antigena (psma) HRP20241082T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650277P 2018-03-29 2018-03-29
EP19717173.9A EP3773910B1 (en) 2018-03-29 2019-03-29 Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates
PCT/US2019/025057 WO2019191728A1 (en) 2018-03-29 2019-03-29 Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates

Publications (1)

Publication Number Publication Date
HRP20241082T1 true HRP20241082T1 (hr) 2024-11-08

Family

ID=66103056

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20241082TT HRP20241082T1 (hr) 2018-03-29 2019-03-29 Konjugati protutijelo-lijek humaniziranog anti-prostata specifičnog membranskog antigena (psma)

Country Status (18)

Country Link
US (2) US12059473B2 (hr)
EP (2) EP4461318A2 (hr)
JP (2) JP7512202B2 (hr)
KR (1) KR20200138759A (hr)
CN (2) CN111989138B (hr)
AU (1) AU2019245444A1 (hr)
BR (1) BR112020019611A2 (hr)
CA (1) CA3094985A1 (hr)
DK (1) DK3773910T3 (hr)
FI (1) FI3773910T3 (hr)
HR (1) HRP20241082T1 (hr)
IL (1) IL277357A (hr)
LT (1) LT3773910T (hr)
MX (1) MX2020010104A (hr)
PT (1) PT3773910T (hr)
SG (1) SG11202009670RA (hr)
SI (1) SI3773910T1 (hr)
WO (1) WO2019191728A1 (hr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021086917A1 (en) * 2019-10-29 2021-05-06 The Cleveland Clinic Foundation Psma-targeting imaging agents
AU2021206218A1 (en) * 2020-01-06 2022-07-07 Cytomx Therapeutics, Inc. Auristatin-related compounds, conjugated auristatin-related compounds, and methods of use thereof
WO2022081443A2 (en) * 2020-10-12 2022-04-21 Memorial Sloan Kettering Cancer Center Anti-psma antibodies and uses thereof
WO2024077277A1 (en) 2022-10-07 2024-04-11 Ambrx, Inc. Drug linkers and antibody conjugates thereof
WO2024178310A1 (en) 2023-02-23 2024-08-29 Ambrx, Inc. Trop2-directed antibody-drug conjugates and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
ATE66469T1 (de) 1985-01-14 1991-09-15 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
SG135176A1 (en) 2004-02-02 2007-09-28 Ambrx Inc Modified human four helical bundle polypeptides and their uses
ES2545533T3 (es) 2004-11-01 2015-09-11 The Regents Of The University Of California Composiciones y métodos para modificación de biomoléculas
AU2015203742B2 (en) 2007-06-26 2016-12-01 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
BRPI0916515B8 (pt) 2008-07-23 2021-07-27 Ambrx Inc polipeptídeo de fator estimulante de colônias de granulócitos bovino (bg-csf), formulação farmacêutica e composição compreendendo o mesmo
DK2714684T3 (en) 2011-05-27 2018-11-26 Ambrx Inc COMPOSITIONS CONTAINING, PROCEDURE INVOLVING, AND APPLICATIONS OF NON-NATURAL AMINO ACID-BONDED DOLASTATIN DERIVATIVES
MX363116B (es) * 2012-06-07 2019-03-11 Ambrx Inc Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata.
SG11201408347UA (en) * 2012-06-14 2015-01-29 Ambrx Inc Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
AU2014329437B2 (en) * 2013-10-06 2018-10-18 F. Hoffmann-La Roche Ag Modified Pseudomonas exotoxin A
JP7179719B2 (ja) 2016-06-06 2022-11-29 ポリセリックス・リミテッド 抗体、その使用及びそのコンジュゲート
GB201614162D0 (en) * 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
EP3630977B1 (en) 2017-06-02 2024-02-21 Ambrx, Inc. Methods and compositions for promoting non-natural amino acid-containing protein production

Also Published As

Publication number Publication date
LT3773910T (lt) 2024-09-25
KR20200138759A (ko) 2020-12-10
DK3773910T3 (da) 2024-08-19
CN117924503A (zh) 2024-04-26
BR112020019611A2 (pt) 2021-01-05
EP4461318A2 (en) 2024-11-13
US20240350835A1 (en) 2024-10-24
SI3773910T1 (sl) 2024-10-30
CN111989138A (zh) 2020-11-24
MX2020010104A (es) 2020-11-06
US12059473B2 (en) 2024-08-13
PT3773910T (pt) 2024-10-22
SG11202009670RA (en) 2020-10-29
EP3773910B1 (en) 2024-07-24
EP3773910A1 (en) 2021-02-17
CA3094985A1 (en) 2019-10-03
AU2019245444A1 (en) 2020-10-01
US20210015940A1 (en) 2021-01-21
IL277357A (en) 2020-11-30
CN111989138B (zh) 2024-02-09
JP7512202B2 (ja) 2024-07-08
FI3773910T3 (fi) 2024-08-29
JP2024123231A (ja) 2024-09-10
JP2021519076A (ja) 2021-08-10
WO2019191728A1 (en) 2019-10-03

Similar Documents

Publication Publication Date Title
HRP20241082T1 (hr) Konjugati protutijelo-lijek humaniziranog anti-prostata specifičnog membranskog antigena (psma)
WO2020236817A8 (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
US20220218837A1 (en) Drug conjugate
Liu et al. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.
JP4959136B2 (ja) 細胞内で開裂可能な結合を有する免疫接合体
CN113423735B (zh) 抗-紧密连接蛋白抗体及其用途
AU687795B2 (en) Lysosomal enzyme-cleavable antitumor drug conjugates
RU2018134331A (ru) Конъюгаты антитело-лекарственное средство на основе эрибулина и способы применения
CN106414465B (zh) 带电荷链接体及其在共轭反应上的应用
HRP20211710T1 (hr) Konjugacija specifična za mjesto spajanja lijekova za povezivanje s protutijelima i konjugati protutijela u lijeku koji nastaje kao rezultat
EP2570137A3 (en) Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
BRPI0615049A2 (pt) processo para a preparação de conjugados de medicamento purificado
Gianolio et al. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody–drug conjugates
JP2016512832A5 (hr)
WO2004073656A3 (en) Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
EP4378958A3 (en) High-affinity anti-mertk antibodies and uses thereof
CN116217729A (zh) 聚糖相互作用化合物及使用方法
CN107043406B (zh) 化合物、连接子-药物、及配体-药物耦合体
RU2019129839A (ru) Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты
IL308504A (en) Antibodies, Antibody Fragments and Their Immunomodules Against ROR2 and Their Uses
PH12021551265A1 (en) Pharmaceutical compositions comprising anti-191p4d12 antibody drug conjugates and methods of use thereof
ES2923853T3 (es) Materiales y métodos relacionados con conectores para su uso en productos conjugados de proteína y fármaco
Li et al. Discovery and activity of STRO-002, a novel ADC targeting folate receptor alpha for ovarian and endometrial cancer
JPWO2021090062A5 (hr)
JPWO2019191728A5 (hr)